Search Results for: NMB

12 interactions involving NMB - neuromedin B found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CCNO cyclin O
Novel CORO2B coronin 2B
Novel FBXL22 F-box and leucine rich repeat protein 22
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel GLCE glucuronic acid epimerase
  • HS-GAG biosynthesis
Novel KIF23 kinesin family member 23
  • MHC class II antigen presentation
  • COPI-dependent Golgi-to-ER retrograde traffic
  • Mitotic Telophase/Cytokinesis
  • Kinesins
Novel MAP2K5 mitogen-activated protein kinase kinase 5
  • Signalling to ERK5
  • Fostamatinib
Novel MRPS5 mitochondrial ribosomal protein S5
  • Mitochondrial translation initiation
  • Mitochondrial translation elongation
  • Mitochondrial translation elongation
  • Mitochondrial translation termination
Novel PTPRZ1 protein tyrosine phosphatase receptor type Z1
  • Other interleukin signaling
BIRC2 baculoviral IAP repeat containing 2
  • Apoptotic cleavage of cellular proteins
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIPK1-mediated regulated necrosis
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR2 non-canonical NF-kB pathway
  • Regulation of necroptotic cell death
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
  • Ub-specific processing proteases
  • IKK complex recruitment mediated by RIP1
GADD45G growth arrest and DNA damage inducible gamma
NMBR neuromedin B receptor
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
TPP1 tripeptidyl peptidase 1
  • XBP1(S) activates chaperone genes
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)

Page 1 out of 1 pages